• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥马珠单抗对惰性系统性肥大细胞增多症的长期成功治疗

Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab.

作者信息

Weiss Samuel L, Hyman John B, Carlson Geoffrey S, Coop Christopher A

机构信息

is an Allergy/Immunology Fellow, and is a Pediatrician, both at San Antonio Uniformed Services Health Education Consortium in Fort Sam Houston, Texas. is an Allergist, and is the Program Director of the Allergy/Immunology Fellowship, both at Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base in Texas.

出版信息

Fed Pract. 2021 Jan;38(1):44-48. doi: 10.12788/fp.0081.

DOI:10.12788/fp.0081
PMID:33574649
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7870274/
Abstract

This case study suggests that omalizumab may help prevent anaphylaxis and reduce disease burden associated with systemic mastocytosis, but further studies and formal clinical trials are needed to confirm these findings.

摘要

该病例研究表明,奥马珠单抗可能有助于预防过敏反应并减轻与系统性肥大细胞增多症相关的疾病负担,但需要进一步的研究和正式的临床试验来证实这些发现。

相似文献

1
Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab.奥马珠单抗对惰性系统性肥大细胞增多症的长期成功治疗
Fed Pract. 2021 Jan;38(1):44-48. doi: 10.12788/fp.0081.
2
Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.奥马珠单抗预防全身性肥大细胞增多症的过敏反应和改善症状:疗效和安全性观察。
Allergy. 2018 Jan;73(1):230-238. doi: 10.1111/all.13237. Epub 2017 Jul 27.
3
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.非侵袭性系统性肥大细胞增多症(SM)无皮肤损伤与昆虫诱导的过敏反应有关,与其他惰性 SM 相比具有独特特征。
J Allergy Clin Immunol. 2014 Feb;133(2):520-8. doi: 10.1016/j.jaci.2013.06.020. Epub 2013 Aug 6.
4
Diagnostic value of tryptase in anaphylaxis and mastocytosis.类胰蛋白酶在过敏反应和肥大细胞增多症中的诊断价值。
Immunol Allergy Clin North Am. 2006 Aug;26(3):451-63. doi: 10.1016/j.iac.2006.05.010.
5
High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.高剂量奥马珠单抗可控制惰性系统性肥大细胞增多症患者对毒液免疫疗法的反复反应。
Allergy. 2008 Mar;63(3):376-8. doi: 10.1111/j.1398-9995.2007.01604.x.
6
Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.奥马珠单抗使一名患有惰性系统性肥大细胞增多症的患者的特发性过敏反应得到缓解。
Acta Derm Venereol. 2014 May;94(3):363-4. doi: 10.2340/00015555-1687.
7
Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.两名系统性肥大细胞增多症患者经奥马珠单抗成功治疗后的皮肤和胃肠道症状
Case Rep Med. 2015;2015:903541. doi: 10.1155/2015/903541. Epub 2015 Jan 28.
8
Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.2例系统性肥大细胞增多症患者接受奥马珠单抗治疗过敏性反应的12年随访
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1314-1316. doi: 10.1016/j.jaip.2018.07.041. Epub 2018 Aug 24.
9
How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).我如何治疗惰性和冒烟型肥大细胞增多症(罕见疾病,但难以治疗)患者。
Blood. 2013 Apr 18;121(16):3085-94. doi: 10.1182/blood-2013-01-453183. Epub 2013 Feb 20.
10
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.KIT D816V 突变负担与惰性系统性肥大细胞增多症的临床表现无关。
J Allergy Clin Immunol. 2013 Sep;132(3):723-728. doi: 10.1016/j.jaci.2013.02.019. Epub 2013 Apr 12.

本文引用的文献

1
Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).奥马珠单抗治疗肥大细胞增多症的疗效:来自前瞻性、双盲、多中心研究(XOLMA 研究)的暗示性结果。
Dermatology. 2020;236(6):529-539. doi: 10.1159/000504842. Epub 2020 Jan 20.
2
Cutaneous mastocytosis treatment: strategies, limitations and perspectives.皮肤肥大细胞增多症的治疗:策略、局限性与展望
Postepy Dermatol Alergol. 2018 Dec;35(6):541-545. doi: 10.5114/ada.2018.77605. Epub 2018 Aug 13.
3
Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.2例系统性肥大细胞增多症患者接受奥马珠单抗治疗过敏性反应的12年随访
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1314-1316. doi: 10.1016/j.jaip.2018.07.041. Epub 2018 Aug 24.
4
Natural history and treatment of cutaneous and systemic mastocytosis.皮肤和系统性肥大细胞增多症的自然病史及治疗
Postgrad Med. 2017 Nov;129(8):896-901. doi: 10.1080/00325481.2017.1364124. Epub 2017 Aug 21.
5
Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.奥马珠单抗预防全身性肥大细胞增多症的过敏反应和改善症状:疗效和安全性观察。
Allergy. 2018 Jan;73(1):230-238. doi: 10.1111/all.13237. Epub 2017 Jul 27.
6
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.肥大细胞增多症:2016年世界卫生组织更新分类及新出现的治疗理念。
Blood. 2017 Mar 16;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893. Epub 2016 Dec 28.
7
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.有助于奥马珠单抗治疗慢性自发性荨麻疹疗效的作用机制。
Allergy. 2017 Apr;72(4):519-533. doi: 10.1111/all.13083. Epub 2017 Jan 4.
8
Mast Cells, Mastocytosis, and Related Disorders.肥大细胞、肥大细胞增多症及相关疾病
N Engl J Med. 2015 Jul 9;373(2):163-72. doi: 10.1056/NEJMra1409760.
9
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.肥大细胞白血病(MCL)和髓肥大细胞白血病(MML)的精细诊断标准与分类:一项共识提议。
Ann Oncol. 2014 Sep;25(9):1691-1700. doi: 10.1093/annonc/mdu047. Epub 2014 Mar 27.
10
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.用于癌症治疗的单克隆抗体的不良事件:聚焦超敏反应。
Oncoimmunology. 2013 Oct 1;2(10):e26333. doi: 10.4161/onci.26333. Epub 2013 Oct 17.